EDITION JP IINueva Formulación de Insulina Glargina y Combinación de Terapia con Lantus® para la Diabetes Mellitus Tipo 2 en Pacientes Japoneses

Fecha de inicio: 1 de septiembre de 2012

Inclusion criteria : o Patients with type 2 diabetes mellitus diagnosed for at least 1 year at the time of screening visit treated with basal insulin in combination with oral antihyperglycemic drugs (OADs) for at least 6 months before screening visit; Exclusion criteria: Age < 18 years at screening visit; BMI(body mass index) ≥ 35 kg/m2 at screening visit; HbA1c < 7.0% or > 10% (national glycohemoglobin standardization program [NGSP] value) at screening visit; Diabetes other than type 2 diabetes mellitus; Patients on self-monitoring of blood glucose less than 6 months before screening visit; Patients using pre-mix insulins, insulin detemir at 2 times or more a day, or GLP 1 receptor agonists in the last 3 months before screening visit; Patients using mealtime insulin (rapid-acting insulin analogue and short-acting insulin) for more than 10 days in the last 3 months before screening visit; Use of insulin pump in the last 6 months before screening visit; Initiation of new glucose-lowering medications and/or weight loss drugs in the last 3 months before screening visit; Severe hypoglycemia resulting in coma/seizures, and/or hospitalization for diabetic ketoacidosis in the last 6 months before screening visit; Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eg, laser, surgical treatment or injectable drugs) during the study period. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.